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Introduction: We aimed to replicate a recent study which showed higher genetic risk load at 15 loci in men than
in women with systemic lupus erythematosus (SLE). This difference was very significant, and it was interpreted as
indicating that men require more genetic susceptibility than women to develop SLE.
Methods: Nineteen SLE-associated loci (thirteen of which are shared with the previous study) were analyzed in
1,457 SLE patients and 1,728 healthy controls of European ancestry. Genetic risk load was calculated as sex-specific
sum genetic risk scores (GRSs).
Results: Our results did not replicate those of the previous study at either the level of individual loci or the global
level of GRSs. GRSs were larger in women than in men (4.20 ± 1.07 in women vs. 3.27 ± 0.98 in men). This very
significant difference (P < 10−16) was more dependent on the six new loci not included in the previous study
(59% of the difference) than on the thirteen loci that are shared (the remaining 41%). However, the 13 shared loci
also showed a higher genetic risk load in women than in men in our study (P = 6.6 × 10−7), suggesting that
heterogeneity of participants, in addition to different loci, contributed to the opposite results.
Conclusion: Our results show the lack of a clear trend toward higher genetic risk in one of the sexes for the
analyzed SLE loci. They also highlight several limitations of assessments of genetic risk load, including the possibility
of ascertainment bias with loci discovered in studies that have included mainly women.Introduction
The large sex bias in systemic lupus erythematosus
(SLE) incidence has not been satisfactorily explained, al-
though sex hormones, cell microchimerism and chromo-
some X dosage seem to be involved [1-4]. There are
other aspects of SLE in addition to incidence in which
patient sex is important [3-6]. They include an increased
prevalence of renal disease, serositis and discoid lupus
and a decrease in the mucocutaneous manifestations in* Correspondence: antonio.gonzalez.martinez-pedrayo@sergas.es
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article, unless otherwise stated.men. Other differences between women and men have
been reported with less consistency between studies as a
higher prevalence of thrombocytopenia, anti–double-
stranded DNA antibodies, decreased C3 and larger organ
damage accrual in men than in women with SLE.
The difference in incidence is maximal during the fer-
tile years. It is preceded by a more similar incidence in
girls and boys before puberty and followed by a return
toward equilibrium in incidence between the sexes in
the eldery. This pattern is a powerful suggestion of the
effect of sex hormones in SLE pathogenesis [1-4]. This
hypothesis is supported by the results of estrogen sup-
pression and estrogen administration experiments in
SLE animal models, but the evidence is less clear inentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in most SLE patients of either sex. Only hyperprolactine-
mia is commonly found, but with uncertain involvement
in disease pathogenesis. In addition, sex hormone ther-
apy is associated with either no or very small increases
in SLE or its severity. Other factors contributing to the
increased SLE incidence in women could be lymphoid
cell microchimerism as a consequence of pregnancy [1].
The incompatibility between the two lymphoid popula-
tions gives rise to autoimmunity in animal models, but
the causal relationship in SLE patients is less clear, as
microchimerism in damaged organs seems to increase as
a consequence of tissue repair [7]. A third factor
explaining the sexual dimorphism of SLE is suspected to
reside in differences between the sex chromosomes
[1-4]. The hypothesized mechanism involves a dose ex-
cess of genes promoting autoimmunity in women due to
noninactivated X chromosomes. This hypothesis has re-
ceived strong support based on the demonstration of an
increased incidence of SLE in patients with Klinefelter’s
syndrome who have an external male phenotype but
carry the XXY sex chromosomes [8].
More recently, evidence supporting the possibility of a
second genetic factor has been reported. Researchers
who analyzed a very large collection of patients of
European ancestry showed that the genetic risk load
was very significantly larger in men than in women
(P = 4.52 × 10−8), based on the sum genetic risk score
(GRSs) of 15 SLE loci [9]. This result was interpreted as
meaning that men require more genetic susceptibility
than women to develop SLE. The difference in genetic
risk load in that study was very dependent on two hu-
man leukocyte antigen (HLA) loci of the fifteen loci in-
cluded. This was shown by the lack of significant
difference between men and women when the two HLA
single-nucleotide polymorphisms (SNPs) were excluded
(P = 0.3). Our interest in the implications of a higher
genetic risk load in men led us to replicate this previous
study, but our results are contrary to those reported. We
found that genetic risk load was very significantly higher
in women than in men with SLE.
Material and methods
Clinical and genotype data
The participant samples used in this study have already
been described [10-12]. Briefly, 17 recruiting centers in
10 European countries were asked for about 100 SLE pa-
tients who met the American College of Rheumatology
criteria [13] and a similar number of healthy controls, all
of whom have uniform ancestry from the country of re-
cruitment. In our present study, samples overlapping
with the Hughes et al. [9] report were considered separ-
ately. Recruiters asked each participant for his or her an-
cestry, and only those reporting uniform known ancestryfrom the respective countries were included. In addition,
we used six top ancestry-informative markers for Euro-
pean population differentiation to determine whether
there were differences between cases and controls from
each recruitment center. Samples from two centers were
excluded because cases and controls showed significant
differences at any of the six top ancestry-informative
markers analyzed, as described previously [11]. This selec-
tion process left us with a total of 1,457 SLE patients and
1,728 healthy controls from 15 collections and 8 countries.
A large fraction of these samples did not overlap with the
previous study of SLE genetic risk load. Specifically, the
nonoverlapping samples were from 1,124 SLE patients
and 1,422 healthy controls from 11 collections and 6
countries. All participants provided their written informed
consent as approved by the respective local ethics com-
mittees: the Ethics Committee for Clinical Research of
Galicia for samples in Santiago and Corunna, the Regional
Ethics Committee for Clinical Research of Asturias for
samples in Oviedo, the Garcia de Orta Hospital Ethics
Committee for samples in Lisbon, the Ethics Committee
of Evangelismos Athens General Hospital and Scientific
Committee of the Euroclinic Hospital for samples in
Athens, the Ethics Committee for Clinical Research of the
Doce de Octubre University Hospital for samples in
Madrid, the Ethical Committee of the Jessenius Medical
Faculty for samples in Martin, the Ethics Committee for
Clinical Research of the Vall d’Hebron Hospital for sam-
ples in Barcelona, the Ethics Committee of the Fonda-
zione IRCCS Cà Granda Ospedale Maggiore Policlinico
for samples in Milan, the Ethical Committee of the Uni-
versity Medical Center Groningen for samples in Gro-
ningen, the Ethics Committee Azienda Ospedaliera San
Camillo–Forlanini for samples in Rome, the Ethical Com-
mittee of the Second University of Naples for samples in
Naples, the Ethics Commission of the Medical School of
Hannover for samples in Hannover, the Commission
d’Ethique Biomédicale Hospitalo–Facultaire de l’Université
Catholique de Louvain for samples in Brussels, the Institu-
tional Ethics Committee of the Hospital of Hungarian State
Railways for Hungarian samples and the Ethical Commit-
tee of the Institute of Rheumatology for samples in
Prague. The overall study was approved by the Comite
Etico de Investigacion Clinica de Galicia. The clinical
characteristics of the patients were obtained at the same
time. These data included the American College of
Rheumatology classification criteria met, sex, age at
time of disease onset and time to follow-up. The
genotypes of 26 SNPs showing the greatest association
at SLE loci identified in large studies [14-23] were avail-
able to us from previous studies [11,12,24]. All have
been genotyped in the same laboratory and with the
same technology: single-base extension using the SNaP-
shot Multiplex Kit (Applied Biosystems, Foster City,
Alonso-Perez et al. Arthritis Research & Therapy 2014, 16:R128 Page 3 of 8
http://arthritis-research.com/content/16/3/R128CA, USA), and have passed quality control filters. Nine-
teen of these SNPs were selected for analysis because
they have reached association with SLE at the genome-
wide association study significant level (P < 5 x 10-8)
and because they were independently associated with
SLE in our samples. Thirteen of these nineteen loci are
shared with the fifteen SNPs included in the GRSs reported
by Hughes et al. [9], and the other six loci have not been
analyzed previously in the context of the sex differential
genetic risk load. The thirteen loci shared between their
studies and ours are listed in the top rows of Table 1, and
the six new loci are listed in the bottom rows. Eleven of
the thirteen shared loci were studied with the same SNPs
used by Hughes et al. [9]; the remaining two loci,
rs17266594 in BANK1 and rs10488631 in IRF5, were stud-
ied with highly correlated SNPs (r2 > 0.9 for rs10516487
and rs2070197, respectively, according to the HapMap data
for the European population).
Analysis of sex-specific genetic risk load
We compared SNP allele frequencies between SLE patients
and controls, women together with men and women and
men separately. Also, allele frequencies were compared be-
tween women and men with SLE. These comparisons were
done by performing χ2 tests. GRSs were obtained byTable 1 List of the 19 systemic lupus erythematosus loci inclu
lupus erythematosus in our samplesa
SNP Gene locusb Chromosome Position
rs2476601 PTPN22 1 114377568
rs1801274 FCGR2A 1 161479745
rs2205960 TNFSF4 1 173191475
rs7574865 STAT4 2 191964633
rs6445975 PXK 3 58370177
rs17266594 BANK1d 4 98488450
rs3131379 MSH5 6 31721033
rs729302 IRF5 7 122930164
rs10488631 IRF5d 7 128594183
rs10954213 IRF5 7 128589427
rs13277113 C8orf13-BLK 8 11349186
rs4963128 KIAA1542 11 589564
rs1143679 ITGAM 16 31276811
rs2304256 TYK2 19 10475652
rs5754217 UBE2L3 22 21939675
rs2230926 TNFAIP3 6 138196066
rs573775 ATG5 6 106764866
rs2187668 HLA-DQA1 6 32605884
rs10798269 1q25.1 1 173309713
aSLE, Systemic lupus erythematosus; SNP, Single-nucleotide polymorphism. bThe 13
in patients with SLE (n = 1,457) and healthy controls (n = 1,728). dr2 = 0.94 with rs1
used for IRF5 by Hughes et al. [9].applying the same approach used by Hughes et al. [9]. In
brief, the number of risk alleles (none, one or two) carried
by a patient at each locus was multiplied by the natural
logarithm of the sex-specific odds ratio (OR) of that locus.
The products corresponding to all loci were summed to
obtain the GRSs for this patient. Only patients with valid
genotypes at all loci were included in this analysis (1,247
women and 125 men with SLE, of whom 981 women and
96 men were nonoverlapping with those in the previous
study). GRSs corresponding to women and men were com-
pared using Student’s t-test. These analyses were done in a
customized version of Statistica 7.0 software (StatSoft,
Tulsa, OK, USA). Power analysis was done using the
Power and Sample Size software [25].
Results
The 19 SNPs that we investigated were significantly dif-
ferent between SLE patients and controls in the unstrati-
fied analysis of our 1,457 SLE patients and 1,728 healthy
controls (Table 1). The direction of change in all loci
was the same as that previously reported [14-22,24]. In
the sex-stratified analysis, the 19 loci were associated in
women (1,321 SLE patients and 1,188 controls) and 9 in
men (136 SLE patients and 540 controls), in part reflect-
ing the decrease in sample size of the male subgroupded in this study and their association with systemic
SLEc Controlc OR (95% CI) P-value
0.099 0.074 1.37 (1.15 to 1.63) 4.3 × 10−4
0.509 0.475 1.15 (1.04 to 1.27) 6.2 × 10−3
0.264 0.217 1.29 (1.15 to 1.45) 1.0 × 10−5
0.323 0.233 1.57 (1.41 to 1.76) 1.2 × 10−15
0.268 0.231 1.22 (1.09 to 1.37) 6.2 × 10−4
0.749 0.711 1.21 (1.09 to 1.36) 6.6 × 10−4
0.145 0.072 2.18 (1.85 to 2.58) 4.2 × 10−21
0.744 0.690 1.31 (1.17 to 1.46) 2.5 × 10−6
0.183 0.101 1.99 (1.72 to 2.31) 1.8 × 10−20
0.680 0.641 1.19 (1.07 to 1.32) 1.1 × 10−3
0.308 0.247 1.35 (1.21 to 1.51) 8.1 × 10−8
0.698 0.656 1.21 (1.09 to 1.34) 5.0 × 10−4
0.236 0.158 1.65 (1.45 to 1.87) 7.0 × 10−15
0.766 0.725 1.24 (1.11 to 1.39) 2.0 × 10−4
0.253 0.216 1.24 (1.10 to 1.39) 3.6 × 10−4
0.074 0.040 1.89 (1.52 to 2.35) 8.5 × 10−9
0.297 0.267 1.16 (1.04 to 1.29) 8.8 × 10−3
0.200 0.106 2.11 (1.83 to 2.43) 1.2 × 10−25
0.729 0.685 1.24 (1.11 to 1.38) 1.3 × 10−4
first loci are shared with those studied by Hughes et al. [1]. cRisk allele frequencies
0516487 used for BANK1 by Hughes et al. [9] and r2 = 0.94 for rs2070197
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women and men with SLE revealed a significant differ-
ence only in rs1143679, the ITGAM SNP, which was
more frequent in men than in women with SLE. Our re-
sults at this locus and at other three loci are in contrast
with those reported by Hughes et al. [9], who found that
the ITGAM SNP was not different and the other three
loci showed significant differences between women and
men with SLE. These differences were an excess of the
risk alleles of two of them in men, rs3131379 in MSH5
(HLA) and rs10488631 in IRF5, and an excess of the
third, rs4963128 in KIAA1542, in women. None of these
changes were observed in our samples (Table 2).
GRSs were obtained separately for women and men
with SLE using the risk alleles and sex-specific ORs of
the 19 loci (Figure 1). They showed very significantly
higher values in women than in men (mean GRSs ±
SD = 4.15 ± 1.07 vs 3.22 ± 1.0, respectively; P < 10−16 by
Student’s t-test). This result was opposite to that observed
by Hughes et al. [9], that is, higher GRSs in men than in
women. The difference was very significant regardless of
consideration of the 77.1% nonoverlapping samples (mean
GRSs ± SD in women = 4.20 ± 1.07 vs 3.27 ± 0.98 in men;
P = 8.9 × 10−16) or of the 22.9% samples overlapping withTable 2 Comparisons of the risk allele frequencies of 19 syste
controls stratified by sex and between men and women with
Menb
SNPc Gene locus SLE Control OR (95% CI) P-value SL
rs2476601 PTPN22 0.114 0.070 1.70 (1.09 to 2.64) 0.017 0.0
rs1801274 FCGR2A 0.493 0.474 1.08 (0.82 to 1.41) 0.6 0.5
rs2205960 TNFSF4 0.257 0.209 1.31 (0.96 to 1.79) 0.09 0.2
rs7574865 STAT4 0.306 0.209 1.67 (1.24 to 2.25) 7.1 × 10−4 0.3
rs6445975 PXK 0.311 0.241 1.42 (1.06 to 1.91) 0.018 0.2
rs17266594 BANK1e 0.730 0.715 1.07 (0.80 to 1.45) 0.6 0.7
rs3131379 MSH5 (HLA) 0.132 0.071 1.98 (1.30 to 3.02) 1.2 × 10−3 0.1
rs729302 IRF5 0.711 0.689 1.11 (0.83 to 1.49) 0.5 0.7
rs10488631 IRF5e 0.184 0.111 1.81 (1.26 to 2.61) 1.2 × 10−3 0.1
rs10954213 IRF5 0.639 0.638 1.01 (0.76 to 1.33) 0.97 0.6
rs13277113 C8orf13-BLK 0.274 0.250 1.13 (0.84 to 1.53) 0.4 0.3
rs4963128 KIAA1542 0.715 0.645 1.38 (1.03 to 1.85) 0.03 0.6
rs1143679 ITGAM 0.299 0.169 2.10 (1.54 to 2.85) 1.6 × 10−6 0.2
rs2304256 TYK2 0.735 0.723 1.06 (0.79 to 1.44) 0.7 0.7
rs5754217 UBE2L3 0.244 0.209 1.22 (0.89 to 1.67) 0.2 0.2
rs2230926 TNFAIP3 0.070 0.039 1.87 (1.07 to 3.27) 0.026 0.0
rs573775 ATG5 0.256 0.263 0.96 (0.71 to 1.30) 0.8 0.3
rs2187668 HLA-DQA1 0.184 0.107 1.87 (1.30 to 2.69) 6.0 × 10−4 0.2
rs10798269 1q25.1 0.733 0.656 1.20 (0.89 to 1.62) 0.2 0.7
aSLE, Systemic lupus erythematosus; SNP, Single-nucleotide polymorphism. bSLE me
cThe 13 first loci are the same as those studied by Hughes et al. [9]. dOR > 1.0 indica
with rs10516487 used for BANK1 and r2 = 0.94 for rs2070197 used for IRF5 [9].those studied by Hughes et al. (3.98 ± 1.07 in women vs
3.05 ± 1.02 in men; P = 1.3 × 10−5). The mean difference in
GRSs between the sexes, 0.93, was the same in the two
subgroups of patients. This result of the overlapping sam-
ples was not reflected in the Hughes et al. study, because
they were only a minor fraction (7.9%) of the samples in-
cluded in that study and they were considered together
with all others.
Differences in the loci investigated between the two
studies include three components: six loci included in
our study that were not in the Hughes et al. study, thir-
teen loci shared by the two studies and two loci in the
Hughes et al. that are absent from our study. The six
loci included only in our study showed either no differ-
ence or a trend toward higher risks in women (Table 2).
Comparison of the GRSs between women and men re-
stricted to these six loci gave a very significant excess
of risk load in women (mean GRSs for these six loci =
1.29 ± 0.55 in women and 0.74 ± 0.46 in men; P < 10−16),
which accounted for most of the difference between the
two sexes in our study (0.55, or 59% of the 0.93 differ-
ence with the 19 loci). The 13 loci that are shared by the
two studies also contributed to the contrasting results,
but less markedly so (mean GRSs of the 13 shared loci =mic lupus erythematosus autosomal loci in patients and
SLEa
Womenb SLE men/SLE women
E Control OR (95% CI) P-value OR (95% CI)d P-value
97 0.076 1.31 (1.08 to 1.60) 7.2 × 10−3 1.19 (0.80 to 1.77) 0.4
11 0.474 1.15 (1.03 to 1.29) 0.011 0.93 (0.72 to 1.20) 0.6
64 0.220 1.27 (1.12 to 1.45) 3.1 × 10−4 0.97 (0.72 to 1.29) 0.8
25 0.243 1.49 (1.32 to 1.69) 2.8 × 10−10 0.92 (0.70 to 1.20) 0.5
64 0.226 1.23 (1.08 to 1.40) 2.2 × 10−3 1.26 (0.96 to 1.66) 0.09
51 0.708 1.24 (1.09 to 1.41) 7.5 × 10−4 0.89 (0.67 to 1.19) 0.4
46 0.072 2.20 (1.82 to 2.66) 9.6 × 10−17 0.89 (0.62 to 1.29) 0.5
48 0.691 1.33 (1.17 to 1.50) 1.0 × 10−5 0.83 (0.63 to 1.10) 0.2
83 0.097 2.09 (1.76 to 2.48) 1.0 × 10−17 1.01 (0.73 to 1.40) 0.96
85 0.643 1.21 (1.07 to 1.36) 1.9 × 10−3 0.82 (0.63 to 1.06) 0.13
11 0.245 1.39 (1.23 to 1.58) 2.8 × 10−7 0.84 (0.63 to 1.11) 0.2
96 0.662 1.17 (1.04 to 1.32) 0.010 1.10 (0.83 to 1.45) 0.5
30 0.153 1.65 (1.42 to 1.90) 1.2 × 10−11 1.43 (1.08 to 1.88) 0.011
70 0.727 1.26 (1.11 to 1.43) 4.8 × 10−4 0.83 (0.62 to 1.11) 0.2
54 0.218 1.22 (1.07 to 1.39) 2.8 × 10−3 0.95 (0.71 to 1.27) 0.7
74 0.041 1.87 (1.45 to 2.40) 7.0 × 10−7 0.95 (0.58 to 1.55) 0.8
01 0.269 1.17 (1.04 to 1.33) 0.012 0.80 (0.60 to 1.06) 0.12
01 0.105 2.15 (1.82 to 2.52) 7.4 × 10−21 0.89 (0.65 to 1.23) 0.5
29 0.680 1.26 (1.12 to 1.43) 1.7 × 10−4 1.02 (0.77 to 1.36) 0.9
n = 136; control men = 540; SLE women = 1,321; Control women = 1,188.
tes higher frequency of the risk allele in men than in women. er2 = 0.94
Figure 1 Sum of genetic risk scores in women and men with
systemic lupus erythematosus. The y-axis represents percentages
of participants in each of the two groups with the sum of genetic
risk scores (GRSs) at the indicated intervals along the x-axis. This
analysis was done with GRSs obtained for each of the 1,247 women
and 125 men with systemic lupus erythematosus (SLE) and 100%
genotype success at the 19 SLE loci. The GRSs of each patient with
SLE is the sum of the products of the natural logarithm of the
sex-specific OR by the number of risk alleles at each locus carried
by the patient, as described by Hughes et al. [9]. Histograms
and distance-weighted least-squares fitting lines for women (light
gray bars and discontinuous line) and for men (dark gray bars
and continuous line) are shown.
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10−7). Their effect is reflected in the remaining 41% of
the mean difference with the 19 loci (0.38 of the 0.93
difference). Therefore, whereas each of the six loci in-
cluded only in our study contributed 0.09 to the mean
difference in GRSs, each of the loci included in both
studies contributed only 0.03 to the average score. We
cannot exclude the possibility that the two loci included
in the previous report that we did not study might have
contributed to the very contrasting results.
Two HLA loci accounted for a large fraction of the
previously reported increased GRSs in men with SLE [9].
We also included two strongly SLE-associated HLA loci
in our analyses (rs3131379 and rs2187668), but they did
not account for a particularly large fraction of the differ-
ence between sexes, as demonstrated by the similar re-
sult obtained after excluding these two SNPs (mean
GRSs except HLA = 3.61 ± 0.81 for women and 2.82 ±
0.76 for men with SLE (P < 10−16), corresponding to 85%
of the difference in GRSs with the 19 loci).
Discussion
Our analysis shows a very significantly higher genetic
risk load in women than in men with SLE. This result is
in striking contrast to the previous analysis by Hughes et al.
[9] and highlights important limitations of this type of
study that prevent firm conclusions about the relativegenetic risk load of the two sexes until these limitations
can be addressed.
The most prominent outcome of our study is the lack
of reproducibility of the results, both at the level of each
locus and at the level of global genetic risk load mea-
sured by GRSs. At the locus level, lack of reproducibility
is well known to have plagued genetic association studies
in the past [26], and it has been notably common in
studies claiming sex-specific associations [27]. Two of
the limitations of these studies are especially relevant
here: tolerant significance thresholds that do not ac-
count for the multiple tests involved and small sample
sizes that lead to imprecision in the estimated effects.
Regarding the significance thresholds, none of the loci
showed a difference between sexes with P < 10−4 in the
two studies. Therefore, all nonreproducible locus associ-
ations will be eliminated if a strict threshold is applied.
This limitation does not apply, however, to the compari-
son of GRSs, because only a test was done in each study
and the results obtained are very significantly different.
In contrast, the second limitation—the decrease in sam-
ple size inherent to stratification by sex—has deleterious
effects in both the analysis of each locus and the calcula-
tion of GRSs. The effect at the locus level can be shown
by comparing, within each study, the power to detect
differences between SLE patients and controls with the
power to detect differences between women and men
with SLE. Our study has enough power (1 − β > 0.8 for
α = 0.05 and risk allele frequency = 0.2) to detect differ-
ences with OR = 1.19 in the first comparison, but only
for OR > 1.52 in the second. Similarly, the Hughes et al.
study [9] has enough power for detection with an OR >
1.12 in the patient–control analysis but an OR > 1.31 in
the female–male comparison. The decrease in power af-
fects the precision of the OR, which is used to calculate
GRSs and, therefore, also has a negative effect in the re-
producibility of the GRSs results. Thus, GRSs, as is true
of other summary parameters, is less variable than the
individual OR included in its calculation, but GRSs per-
formance depends on the OR quality, which is deter-
mined by sample size and the minor allele frequency of
the SNPs [28].
A second notable message derived from the data is
that most known SLE loci are not clearly biased to more
risk in one of the sexes. In our study, only one of the
nineteen SNPs showed a significant difference between
women and men with SLE. The risk allele of this SNP
(rs1143679) in ITGAM was more associated with SLE
in men than in women. Similar results were reported
by Hughes et al. [9], who showed that only four loci
(rs1270942 in the HLA, rs3131379 in MSH5 (HLA),
rs10488631 in IRF5, and rs4963128 in KIAA1542) of
the fifteen analyzed had significant differences between
women and men with SLE. They found that the risk
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than in women with SLE, but the fourth (in KIAA1542)
was more common in women than in men with SLE. In
addition, when the Bonferroni correction is applied for
the number of loci analyzed, only the two HLA loci in-
cluded in the Hughes et al. study remain significantly
different between the sexes in either of the two studies.
Given this lack of clear bias for most SLE loci to excess
risk in one of the sexes, differences in estimated global
genetic risk load will be sensitive to the inclusion of loci
showing small and inconsistent differences, with some
showing a small bias toward one sex and others to the
opposite sex. The balance between the two components
will determine the global outcome. In addition, solving
the question of the different genetic risk load in women
and men will be difficult until we know a larger fraction
of the heritability of SLE than the current 9% to 15%
[16,29]. This fraction of heritability has be explained
with up to 23 loci, but the most current estimates put
the number of loci for complex diseases such as SLE at
several hundred [30]. These estimates indicate that many
of the yet undiscovered loci will show lower effects than
those already known. However, it is clear that there is
plenty of room for improvement. Larger coverage of SLE
heritability will permit more reproducible assessment of
differences in the total genetic burden between the sexes.
The very significant differences (P < 10−16 and P < 5 ×
10−8) in genetic risk load in the two studies indicate that
there are factors other than the imprecision of GRSs
leading to their opposite directions. Two factors are
likely to have been major contributors: the different sets
of loci and the differences between the participants in-
cluded. Our analysis shows that the different sets of loci
in each study were an important factor. The six loci we
explored that were not included in the previous study
accounted for more than one-half of the excess risk in
women, despite representing less than one-third of the
analyzed loci. In addition, it is very likely that lack of the
HLA SNP rs1270942 in our study also contributed to
the contrasting results, because it accounted for the
highest risk in men of all the loci included in the Hughes
et al. study [9]. Regarding the differences between the
study participants, they are shown by the significantly
higher risk load in women than in men in our study
(P < 6.6 × 10−7), based on the GRSs calculated for the 13
loci shared by the two studies. The differences between
the two studies could include genetic heterogeneity af-
fecting both patients with SLE and controls and clinical
differences between the patients with SLE. Genetic het-
erogeneity is especially likely at the HLA SNPs, where
large differences, even within subpopulations of the
same ethnic group, are common. The two types of het-
erogeneity, genetic and clinical, have previously been
shown to be reflected in the degree of association of SLEloci [11,31-34]. In this regard, we could compare the
prevalence of only three SLE classification criteria, but
they showed significant heterogeneity between the SLE
patients included in the two studies. Men in the Hughes
et al. study had a higher prevalence of renal disease
(OR = 1.7, P = 1.2 × 10−5) than that in women, but not of
serositis or neurologic involvement [9]. In contrast, the
men in our study had a higher incidence of serositis
than the women did (OR = 1.58, P = 0.017), but not renal
(OR = 1.23, P = 0.3) or neurologic involvement. This
type of inconsistency between studies regarding clinical
differences between women and men with SLE are
common [3-6].
There is an additional point to consider in the inter-
pretation of this type of study: the possibility of ascer-
tainment bias. This artefact is the systematic deviation
from the true population value that is attributable to the
sampling processes used to find SNPs and estimate their
population-specific allele frequencies [35]. As all the SLE
loci have been discovered in studies involving either only
women or a very dominant fraction of women, they re-
flect more faithfully genetic susceptibility to SLE in
women than in men. Therefore, they are more likely to
show stronger associations with women than with men,
in cases where the genetic susceptibility of the two sexes
is different. The possibility of ascertainment bias means
that the increased genetic risk load we found in women
cannot be interpreted as a more marked genetic compo-
nent in SLE susceptibility in women than in men.
Conclusions
Our results highlight that there is not a uniform trend in
the known SLE loci toward higher genetic risk in one or
the other of the sexes among Europeans. In addition,
our results show the multiple limitations of studies in
which investigators aim to establish sex-specific genetic
risk loads in SLE. These limitations include the critical
role of the assortment of loci that are considered in a
particular study; the imprecision in GRSs estimates for
men; heterogeneity between sets of participants, includ-
ing genetic and clinical heterogeneity; and the possibility
of ascertainment bias when analyzing loci identified pre-
dominantly in women. The limitations could someday
be addressed in studies in which researchers include
SNPs representing a larger fraction of the SLE genetic
component of what is currently known and that have
been identified in large samples of both women and
men; however, such studies are not currently possible.
Therefore, at present, these limitations prevent assess-
ment with confidence of differences in genetic load be-
tween women and men with SLE.
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